Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome

Diabetic Medicine

Volumn 21, Issue 8, 2004, Pages 829-836

  Glueck, C J ^a,b   Bornovali, S ^a   Pranikoff, J ^a   Goldenberg, N ^a   Dharashivkar, S ^a   Wang, P ^a  

^a JEWISH HOSPITAL   (United States)

^b American Baptist College Inc   (United States)

Author keywords

Gestational diabetes; Metformin; Polycystic ovary syndrome; Pre eclampsia

Indexed keywords

METFORMIN;

ADULT; ARTICLE; BIRTH DEFECT; BIRTH WEIGHT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HELLP SYNDROME; HUMAN; MACROSOMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BIRTH WEIGHT; BODY WEIGHT; DIABETES, GESTATIONAL; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; METFORMIN; PARITY; POLYCYSTIC OVARY SYNDROME; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 3843127654     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01251.x     Document Type: Article

References (40)

1. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75: 46-52.
2. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858-2864.
3. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524-529.
4. Heard MJ, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002; 77: 669-673.
5. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520-525.
6. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002; 3: 1177-1189.
7. Glueck CJ, Goldenberg N, Streicher P, Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002; 3: 1557-1568.
8. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909-933.
9. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 2003; 88: 1323-1332.
10. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001; 63: 1747-1756.
11. Coetzee EJ, Jackson WP. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1985; 1: 281-287.
12. Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65: 635-637.
13. Coetzee EJ, Jackson WP. Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 1980; 58: 795-802.
14. Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979; 16: 241-245.
15. Jackson WP, Coetzee EJ. Side-effects of metformin. S Afr Med J 1979; 56: 1113-1114.
16. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17: 507-511.
17. American College of Obstetricians and Gynecologists (ACOG). Diagnosis and management of pre-eclampsia and eclampsia. Practice bulletin number 33. Int J Gynaecol Obstet 2002; 77: 67-75.
18. Lynch A, McDuffle R, Murphy J, Kaber K, Orleans M. The role of assisted reproductive technologies in the Netherlands. Obstet Gynecol 2002; 99: 445-451.
19. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardottir S et al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet 2001; 9: 758-764.
20. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16: 226-229.
21. Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002; 87: 1563-1568.
22. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 1999; 94: 194-197.
23. de Vries MJ, Dekker GA, Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study. Eur J Obstet Gynecol Reprod Biol 1998; 76: 91-95.
24. Fridstrom M, Nisell H, Sjoblom P, Hillensjo T. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? Hypertens Pregnancy 1999; 18: 73-80.
25. Kashyap S, Claman P. Polycystic ovary disease and the risk of pregnancy-induced hypertension. J Reprod Med 2000; 45: 991-994.
26. Ferriman D, Gallwey J. Clinical assessment of body hair growth in women. Endocrinol Metab Clin North Am 1961; 21: 1440-1447.
27. Kawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: a rational approach. In: Dunaif A, Givens JR, Haseltine F et al., eds. Polycystic Ovary Syndrome. Cambridge, MA: Blackwell, 1992, 377-384.
28. Fauser BCJM, Balen A, Tarlatzis BC. ESHRE/ASRM PCOS consensus session. Human Reproduction 2003; 18: xviii48.
29. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002; 57: 755-767.
30. Sowers M, Crawford SL, Cauley JA, Stein E. Association of lipoprotein (a), insulin resistance, and reproductive hormones in a multiethnic cohort of pre- and perimenopausal women. The SWAN study. Am J Cardiol 2003; 92: 533-537.
31. Branch D, Porter T. Hypertensive disorders of pregnancy. In: Scott, J Di Saia, P Hammond, C, Spellacy, W, eds. Danforth's Obstetrics and Gynecology, 8th edn. Lippincott: Williams & Wilkins, 1999.
32. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
33. Abraham KA, Connolly G, Farrell J, Walshe JJ. The HELLP syndrome, a prospective study. Ren Fail 2001; 23: 705-713.
34. American Diabetes Association. Position statement - gestational diabetes. Diabetes Care 1986; 9: 430-431.
35. O'Sullivan JB, Mahan CM, Charles D, Dandrow RV. Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol 1973; 116: 895-900.
36. Zhang J, Bowes WA Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstet Gynecol 1995; 86: 200-208.
37. SAS/STAT. Changes and enhancements through Release 8.02. Cary, NC: SAS/STAT, 2002.
38. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002; 54: 94-98.
39. Sanchez SE, Zhang C, Malinow RM, Ware-Jauregui S, Larrabure G, Williams MA. Plasma folate, vitamin B (12), and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women. Am J Epidemiol 2001; 153: 474-480.
40. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-el R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003; 18: 721-727.